Veracyte shares surge 11.16% premarket after Q3 revenue jumps 14% to $131.9M and EBITDA margin hits 30%.

Veracyte Inc. (VCYT) surged 11.16% in premarket trading following the release of its third-quarter 2025 financial results, which showed 14% year-over-year revenue growth to $131.9 million and a 30.1% adjusted EBITDA margin. The company raised full-year revenue guidance to $506–$510 million and adjusted EBITDA margin forecasts, citing strong performance in its Decipher and Afirma testing segments. Canaccord Genuity also raised its price target to $43 from $40, citing the company’s margin expansion and operational execution. The stock’s sharp premarket rise aligned with the positive earnings report, which highlighted robust revenue growth, margin expansion, and strategic product launches, reinforcing investor confidence in Veracyte’s long-term growth trajectory.